Latest immunosuppression Stories

Findings could help provide better donor-recipient matches and tailor recipients' treatments after kidney transplantation Highlights: -The detection of preformed donor-specific antibodies by newer tests, despite negative results from traditional tests, nearly doubles a kidney transplant recipient's risk for rejection. -It also increases the risk of kidney failure by 76%. Nearly 17,000 kidney transplants take place each year in the United States. Kidney transplant recipients who...

DPC Urges Swift Passage of Bill to Extend Drug Coverage for Transplant Patients WASHINGTON, Sept. 18, 2012 /PRNewswire-USNewswire/ -- Data from a recent survey of Dialysis Patient Citizens' (DPC) kidney disease patient membership highlights the strong need for swift Congressional action on the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011 (H.R. 2969/S.1454). The survey data released today reinforces concerns that many dialysis patients are...

CHILLY-MAZARIN, France, June 14, 2012 /PRNewswire/ -- InGen BioSciences, specialised in the development and commercialisation of mono and multiparametric in vitro diagnostic tests announced a new exclusive partnership with Cylex Incorporated (Columbia, Maryland,...

HORSHOLM, Denmark, May 23, 2012 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that it contemplates restructuring the company's operations in order to fully focus its resources on the completion of the development and subsequent commercialization of LCP-Tacro(TM), Veloxis' product candidate for the prevention of organ rejection. It is planned that a discontinuation of other pipeline activities will take place, including early phase research activities. The...

Statins prevent cancer and reduce death from all causes in heart transplant recipients. The findings were independent of cholesterol levels. The research was presented at the Heart Failure Congress 2012, 19-22 May, in Belgrade, Serbia. The Congress is the main annual meeting of the Heart Failure Association of the European Society of Cardiology. Cancer is the leading cause of death late after heart transplantation. Skin cancer is particularly common, but solid organ cancers including...

(Ivanhoe Newswire) - Cancer is the leading cause of death late after heart transplantation. Now, new research shows that statins, immunomondulatory drugs, may benefit patients beyond their lipid lowering effects. Researchers in Zurich are currently investigating the impact of statin therapy on the occurrence of cancer and death from causes in heart transplantation recipients. They found the increased rate of cancer in heart transplant recipients may be related to the immune suppression of...

HORSHOLM, Denmark, March 29, 2012 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that enrolment has been completed in its pivotal LCP-Tacro Phase III study in de novo kidney transplant patients. The LCP-Tacro 3002 study is designed to demonstrate non-inferiority versus the gold standard therapy Prograf® and has randomized over 540 patients at approximately 90 clinical sites around the world. "With the results of our 3001 study already complete and our 3002...

MIAMI, March 20, 2012 /PRNewswire-USNewswire/ -- New findings from a transplant study led by scientists from the Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine and a DRI Federation center at Xiamen University in China showed that mesenchymal stem cells may replace a powerful anti-rejection drug in transplant recipients. The results of this pioneering study involving kidney transplant patients is published in the March 21 issue of the Journal...

First-of-its-kind study where donor, recipient are not related or immunologically matched CHICAGO, March 7, 2012 /PRNewswire-USNewswire/ -- New ongoing research published today in the journal Science Translational Medicine suggests organ transplant recipients may not require anti-rejection medication in the future thanks to the power of stem cells, which may prove to be able to be manipulated in mismatched kidney donor and recipient pairs to allow for successful transplantation...

Pilot study shows 60 percent of children who received liver tissue from a parent can safely discontinue immunosuppression; larger study planned Physicians at three transplant centers have found in a pilot study that a majority of children who receive liver tissue from a parent can eventually stop using immunosuppression (anti-rejection) medications safely. These drugs, which tamp down natural immune function, have been linked to a bevy of complications, including cancer, diabetes,...